Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study (DAKI-CKD)
AKI - Acute Kidney Injury, Biomarkers, Transition to CKD
About this trial
This is an interventional prevention trial for AKI - Acute Kidney Injury focused on measuring AKI, Biomarkers, no recovery
Eligibility Criteria
Inclusion Criteria: Adults (aged >18 years) with AKI 3 diagnosis for less than 24 h (KDIGO classification, creatinine level or urine output criteria), hospitalized in general admission floor and/or intensive care unit. AKI diagnosis must be compatible with the diagnosis of acute tubular necrosis in a context of ischemic or toxic aggression. Exclusion Criteria: CKD Stage 3b (KDIGO) or more, renal transplant, urinary tract obstruction, thrombotic microangiopathy, acute glomerulopathy, cardiac arrest without awakening, oncological diagnosis with a life expectancy of less than 5 years, use of norephinephrine >0.30 mcg/kg/min for 6 h or more, use of two vasopressors, PaO2/FiO2 ratio <150, Type 1 DM, fasting for more than 48 h, previous inclusion in other study, pregnant or breastfeeding woman.
Sites / Locations
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Dapaglifozin group
Standard of care
Dapagliflozin 10 mg, will be administered orally or by nasogastric tube every 24 h for 21 days.
Without receiving any of the interventional drugs.